Tetrodotoxin-sensitive Na+ channels and muscarinic and purinergic receptors identified in human erythroid progenitor cells and red blood cell ghosts

被引:38
作者
Hoffman, JF
Dodson, A
Wickrema, A
Dib-Hajj, SD
机构
[1] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA
[2] Penn State Coll Med, Hershey, PA 17033 USA
[3] Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA
[4] Yale Univ, Sch Med, Vet Assoc Neurosci Res Ctr, Paralyzed Vet Assoc Eastern Paralyzed, West Haven, CT 06516 USA
关键词
D O I
10.1073/pnas.0404228101
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article concerns the identification of different types of voltage-gated Na+ channels and of muscarinic and purinergic receptors that are expressed in human erythroid precursor cells and red cell ghosts. We analyzed, by RT-PCR, RNA that was extracted from purified and synchronously growing human erythroid progenitor cells, differentiating from erythroblasts to reticulocytes in 7 to 14 days. These extracts were free of white cell and platelet contamination. Two types of voltage-gated, tetroclotoxin-sensitive Na+ channels were found. These were Na(v)1.4 and Na(v)1.7, the former known to be present in skeletal muscle and the latter in peripheral nerve. By using a pan Na+ channel antibody and Western blotting, an immunoreactive channel was detected in ghosts of human red blood cells, consistent with the expression of these two channels. The transcripts for four of the five known subtypes of muscarinic receptors were also identified, including subtypes M2, M3, M4, and M5, whereas subtype M1 was not found. Expression was also detected for the purinergic type receptors P2X(1), P2X(4), P2X(7), and P2Y(1) whereas types P2Y(2), P2y(4), and P2Y(6) were not found. We also searched for but did not find transcripts for hBNP-1, a type 1b human brain sodium phosphate cotransporter, and cystic fibrosis transmembrane conductance regulator (CFTR). Implications regarding the presence of these different types of channels and receptors in human red blood cells and their functional significance are discussed.
引用
收藏
页码:12370 / 12374
页数:5
相关论文
共 55 条
[1]   Erythrocyte membrane ATP binding cassette (ABC) proteins: MRP1 and CFTR as well as CD39 (ecto-apyrase) involved in RBC ATP transport and elevated blood plasma ATP of cystic fibrosis [J].
Abraham, EH ;
Sterling, KM ;
Kim, RJ ;
Salikhova, AY ;
Huffman, HB ;
Crockett, MA ;
Johnston, N ;
Parker, HW ;
Boyle, WE ;
Hartov, A ;
Demidenko, E ;
Efird, J ;
Kahn, J ;
Grubman, SA ;
Jefferson, DM ;
Robson, SC ;
Thakar, JH ;
Lorico, A ;
Rappa, G ;
Sartorelli, AC ;
Okunieff, P .
BLOOD CELLS MOLECULES AND DISEASES, 2001, 27 (01) :165-180
[2]   Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells [J].
Adrian, K ;
Bernhard, MK ;
Breitinger, HG ;
Ogilvie, A .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2000, 1492 (01) :127-138
[3]   Phorbol ester stimulates a protein kinase C-mediated agatoxin-TK-sensitive calcium permeability pathway in human red blood cells [J].
Andrews, DA ;
Yang, L ;
Low, PS .
BLOOD, 2002, 100 (09) :3392-3399
[4]   MUSCARINIC CHOLINERGIC BINDING IN HUMAN ERYTHROCYTE-MEMBRANES [J].
ARONSTAM, RS ;
ABOOD, LG ;
MACNEIL, MK .
LIFE SCIENCES, 1977, 20 (07) :1175-1180
[5]  
AUGUSTINSSON KB, 1948, ACTA PHYSIOL SCA S52, V15, P1
[6]  
BENNEKOU P, 2003, RED CELL MEMBRANE TR
[7]  
BERNIE CO, 1989, MOL PHARMACOL, V35, P526
[8]   RECEPTOR-EFFECTOR COUPLING BY G-PROTEINS - PURIFICATION OF HUMAN-ERYTHROCYTE GI-2 AND GI-3 AND ANALYSIS OF EFFECTOR REGULATION USING RECOMBINANT ALPHA-SUBUNITS SYNTHESIZED IN ESCHERICHIA-COLI [J].
BIRNBAUMER, L ;
CODINA, J ;
MATTERA, R ;
YATANI, A ;
GRAF, R ;
OLATE, J ;
SANFORD, J ;
BROWN, AM .
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1988, 53 :229-239
[9]  
BOYER JL, 1989, J BIOL CHEM, V264, P884
[10]   Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): High throughput assays in mammalian cells [J].
Bräuner-Osborne, H ;
Brann, MR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 295 (01) :93-102